Abstract
The XIENCE V SPIRIT WOMEN study will focus on specific aspects of women's health in relation to coronary artery disease, such as menopausal status, use of hormonal contraceptives or their surrogates, and the referral path and symptoms at presentation. The study is a prospective, open-label, single-arm, multicenter study designed to evaluate the performance of the XIENCE V Everolimus-Eluting Coronary Stent System in the treatment of female patients with coronary artery lesions. It also includes a prospective, single-blind, double-arm, randomized, multicenter substudy, in which patients will be randomized in a 2:1 ratio between the XIENCE V stent and the CYPHER Plus. In total, approximately 2000 female patients, derived from the general interventional cardiology population, will be enrolled from up to 130 sites outside of the USA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
